Recent progress on tyrosine kinase 2 JH2 inhibitors

Int Immunopharmacol. 2023 Aug:121:110434. doi: 10.1016/j.intimp.2023.110434. Epub 2023 Jun 12.

Abstract

Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family, which can regulate the signaling of multiple pro-inflammatory cytokines, including IL12, IL23 and type I interferon (IFNα/β), and its inhibitors can treat autoimmune diseases caused by the abnormal expression of IL12 and IL23. Interest in TYK2 JH2 inhibitors has increased as a result of safety concerns with JAK inhibitors. This overview introduces TYK2 JH2 inhibitors that are already on the market, including Deucravactinib (BMS-986165), as well as those currently in clinical trials, such as BMS-986202, NDI-034858, and ESK-001.

Keywords: Autoimmune diseases; BMS-986202; Deucravacitinib; JH2 inhibitor; Tyrosine kinase 2 (TYK2).

Publication types

  • Review

MeSH terms

  • Interleukin-12
  • Janus Kinase Inhibitors*
  • Janus Kinases / metabolism
  • Signal Transduction
  • TYK2 Kinase* / metabolism

Substances

  • TYK2 Kinase
  • Janus Kinases
  • Janus Kinase Inhibitors
  • Interleukin-12